Eslamian Gelareh, Wilson Caroline, Young Robin J
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
Onco Targets Ther. 2017 Feb 13;10:773-779. doi: 10.2147/OTT.S102638. eCollection 2017.
Eribulin is a novel microtubule-targeting agent that is approved for the treatment of patients with locally advanced or metastatic breast cancer who have previously received treatment with an anthracycline and a taxane in either the adjuvant or metastatic setting. Eribulin induces mitotic catastrophe leading to cell death but has other important antitumor effects, including reversal of epithelial-mesenchymal transition and remodeling of the tumor vasculature. Eribulin was licensed for the treatment of advanced breast cancer based on results from two large randomized Phase III clinical trials. Current clinical trials of eribulin for breast cancer are evaluating response to treatment earlier in the patient pathway and in combination with other therapeutic agents. This review provides a short overview of emerging new data on the mode of action of eribulin in breast cancer.
艾日布林是一种新型微管靶向药物，被批准用于治疗局部晚期或转移性乳腺癌患者，这些患者在辅助或转移性治疗中曾接受过蒽环类药物和紫杉烷类药物治疗。艾日布林可诱导有丝分裂灾难导致细胞死亡，但还有其他重要的抗肿瘤作用，包括逆转上皮-间质转化和重塑肿瘤血管。基于两项大型随机III期临床试验的结果，艾日布林被批准用于治疗晚期乳腺癌。目前关于艾日布林治疗乳腺癌的临床试验正在评估患者治疗早期的反应以及与其他治疗药物联合使用的效果。本综述简要概述了艾日布林在乳腺癌作用机制方面的新出现的数据。
